Crossmark

Auto-antibodies against type I IFNs in > 10% of critically ill COVID-19 patients: a prospective multicentre study

Crossref DOI link: https://doi.org/10.1186/s13613-022-01095-5

Published Print: 2022

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Arrestier, Romain

Bastard, Paul

Belmondo, Thibaut

Voiriot, Guillaume

Urbina, Tomas

Luyt, Charles-Edouard

Gervais, Adrian

Bizien, Lucy

Segaux, Lauriane

Ben Ahmed, Mariem

Bellaïche, Raphaël

Pham, Taï

Ait-Hamou, Zakaria

Roux, Damien

Clere-Jehl, Raphael

Azoulay, Elie

Gaudry, Stéphane

Mayaux, Julien

Fage, Nicolas

Ait-Oufella, Hafid

Moncomble, Elsa

Parfait, Mélodie

Dorgham, Karim

Gorochov, Guy

Mekontso-Dessap, Armand

Canoui-Poitrine, Florence

Casanova, Jean-Laurent

Hue, Sophie

de Prost, Nicolas https://orcid.org/0000-0002-4833-4320
License Information

Text and Data Mining valid from 2022-01-01

Text and Data Mining valid from 2022-01-01

Version of Record valid from 2025-11-19
More Information

This article is maintained by: Elsevier

Article Title: Auto-antibodies against type I IFNs in > 10% of critically ill COVID-19 patients: a prospective multicentre study

Journal Title: Annals of Intensive Care

CrossRef DOI link to publisher maintained version: https://doi.org/10.1186/s13613-022-01095-5

Content Type: article

Copyright: Copyright © 2022 The Author(s) 2022. Published by Elsevier Masson SAS